TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32468087
Drug: Nangibotide (0.3,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nangibotide (0.3, 1.0, or 3.0 mg/kg/h)
Study: 36104719
Drug: MRV-MNP and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRV-MNP and placebo (0.9% sodium chloride) subcutaneous injection
Study: 36104719
Drug: Placebo MNP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo MNP and MRV by subcutaneous injection (MRV-SC)
Study: 33705543
Drug: Lifestyle or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle or metformin interventions
Study: 34118609
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral pyridoxine (100-300 mg/kg/day) in combination with ACTH (150 IU/m2/day)
Study: 34118609
Drug: Standard ACTH
Normalized name: ACTH
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard ACTH therapy alone
Study: 35235659
Drug: Exenatide (EXE),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (EXE), 5 μg s.c.
Study: 35235659
Drug: Dapagliflozin (DAPA),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dapagliflozin (DAPA), 10 mg
Study: 35835685
Drug: Acupressure (36
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure (36 min, three times weekly for one month)
Study: 33027644
Drug: Mineralocorticoid receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineralocorticoid receptor antagonists (MRA)
Study: 34693933
Drug: Nonnucleoside reverse
Normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonnucleoside reverse transcriptase inhibitor (nNRTI) based ART
Study: 33567423
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (800 mg + 5 μg Vitamin D)
Study: 33567423
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate (1,000 mg)
Study: 32847991
Drug: Occupational exposures
Normalized name: Bacillus anthracis strain V770-NP1-R antigens
DrugBank: Anthrax vaccine (DB11003)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational exposures (22 agents)
Study: 33798731
Drug: PATH intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PATH intervention (online portal and twice a month phone calls from a PA coach)
Study: 33798731
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control group (self-help PA handout and twice a month general health newsletter)
Study: 33344752
Drug: Intravenous allopregnanolone
Normalized name: Allopregnanolone
DrugBank: Brexanolone (DB11859)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous allopregnanolone
Study: 35289043
Drug: Topical latanoprost
Normalized name: Latanoprost
DrugBank: Latanoprost (DB00654)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Topical latanoprost 0.005% solution
Study: 32568601
Drug: Weekend physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekend physical therapy services in the sub-acute setting (Phase 2, n = 130)
Study: 32568601
Drug: Weekend physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekend physical therapy services in the acute setting (Phase 1, n = 117)
Study: 33913511
Drug: secukinumab 300
Normalized name: secukinumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: secukinumab 300 mg via subcutaneous injection at baseline, week 1-4, and then every 4 weeks until week 48
Study: 33913511
Drug: adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: adalimumab 40 mg via subcutaneous injection every 2 weeks from baseline until week 50
Study: 32730096
Drug: Pivotal Response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pivotal Response Treatment
Study: 32730096
Drug: Robot-assisted Pivotal
Normalized name: PIVOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Robot-assisted Pivotal Response Treatment
Study: 35596774
Drug: Alpha-lipoic acid
Normalized name: Alpha-lipoic acid
DrugBank: Lipoic acid (DB00166)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha-lipoic acid (ALA) 600 mg once daily for 6 months
Study: 34920155
Drug: 150 mM
Normalized name: Tenscare Electrodes Joint 150 mm Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mM calcium lactate solution followed by 0.05% sodium fluoride solution (Ca→F)
Study: 34920155
Drug: 150 mM
Normalized name: Tenscare Electrodes Joint 150 mm Pad
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mM calcium lactate solution premixed with 0.05% sodium fluoride solution (CaF2, active control)
Study: 33827659
Drug: Comprehensive pre‐pregnancy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive pre‐pregnancy lifestyle intervention to promote weight loss with ongoing treatment until conception
Study: 32553151
Drug: IONIS-DGAT2Rx (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: IONIS-DGAT2Rx (250 mg, once weekly for 13 weeks)
Study: 33211592
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose (4.03 mmol) of inorganic nitrate
Study: 33211592
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose (8.06 mmol) of inorganic nitrate
Study: 34819434
Drug: Operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Operative treatment (open reduction and internal fixation using tension band wiring)
Study: 34819434
Drug: Non-operative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-operative treatment (boot cast)
Study: 37690669
Drug: Molnupiravir (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molnupiravir (800 mg twice daily for 5 days)
Study: 35962311
Drug: Ice water
Normalized name: CVS Electrolyte Solution with Zinc (Rice Water)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ice water injection (250 ml) toward the duodenal papilla at the end of ERCP
Study: 35962311
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no ice water injection)
Study: 33136077
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy program for the upper limb
Study: 32914852
Drug: Family-based behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Family-based behavioral obesity treatment (FBT) for 4 months
Study: 35609671
Drug: Escitalopram (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escitalopram (up to 20 mg)
Study: 32686487
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment (testing, in-person feedback, and two calls from a care-coordinator)
Study: 32686487
Drug: Standard-care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-care treatment (neuropsychological testing and phone feedback)
Study: 32686487
Drug: Experimental treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental treatment and Standard-care treatment
Study: 32686487
Drug: Standard-care treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-care treatment
Study: 33593341
Drug: Passive physical
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Passive physical treatment
Study: 33593341
Drug: Active physical
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active physical treatment
Study: 37552083
Drug: Inappropriate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate therapy
Study: 33706065
Drug: Topical ozonated
Normalized name: ozone
DrugBank: Ozone (DB12510)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ozonated oil, applied twice a day for 60 days
Study: 33706065
Drug: Placebo (non-ozonated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (non-ozonated oil), applied twice a day for 60 days
Study: 33770365
Drug: Daratumumab in
Normalized name: daratumumab Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daratumumab in combination with bortezomib, melphalan, and prednisone (D-VMP)
Study: 32035692
Drug: Standard chemoradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard chemoradiation combined with recombinant human endostatin injection (Endostar)
Study: 35109763
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg vitamin B6 daily
Study: 37589610
Drug: Patient-activation tool
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-activation tool for intensification of medications for chronic heart failure
Study: 32739670
Drug: Transitional care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transitional care intervention including risk assessment for early readmission, health education from admission to predischarge, individualized discharge planning, and weekly telephone follow-up for one month and WeChat follow-up postdischarge.
Study: 32994020
Drug: Resveratrol/ethanol 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resveratrol/ethanol 10 mg/mL
Study: 32994020
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (0 mg/mL resveratrol/ethanol)
Study: 35691791
Drug: Intranasal gonadorelin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal gonadorelin treatment
Study: 35691791
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no gonadorelin treatment)
Study: 32622768
Drug: Novel penile
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Novel penile splint (Early Traction Therapy - ETT) applied post-surgery
Study: 33250386
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg mint nicotine gum
Study: 35417188
Drug: Bifidobacterium infantis
Normalized name: Bifidobacterium infantis
DrugBank: Bifidobacterium longum infantis (DB14222)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium infantis (EVC001) administered daily for 28 days
Study: 33196773
Drug: Withholding standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Withholding standard intravenous empirical antibiotics for 48 hours after birth
Study: 33196773
Drug: Standard intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard intravenous empirical antibiotics for 48 hours after birth
Study: 35079088
Drug: 3CLpro inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 3CLpro inhibitor PF-07321332
Study: 34601410
Drug: Traffic-polluted road
Normalized name: Road to Wellness KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traffic-polluted road walking treatment
Study: 34601410
Drug: Traffic-free park
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traffic-free park walking treatment
Study: 32887557
Drug: 2 L/min
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 L/min O2
Study: 32359741
Drug: 500 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg/day curcuminoids
Study: 32359741
Drug: 50,000 IU/week
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000 IU/week vitamin D3 plus 500 mg/day curcuminoids
Study: 34871182
Drug: CERC-002 (human
Approvals — FDA: no, EMA: no, PMDA: no
Description: CERC-002 (human LIGHT-neutralizing antibody)
Study: 32722015
Drug: Experimental group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental group (EG) - dairy preparation enriched in calcium, vitamin D, vitamin K, vitamin C, zinc, magnesium, L‐leucine and probiotic (Lactobacillus plantarum 3547) consumed daily for 24 weeks
Study: 36280804
Drug: Opioid-free anesthesia
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opioid-free anesthesia (OFA) regimen including IV magnesium sulfate, lidocaine, ketamine, dexamethasone, propofol, rocuronium, isoflurane, and continuous infusion of magnesium sulfate, ketamine, and clonidine
Study: 36263942
Drug: L-theanine 200
Normalized name: L-theanine 200 MG Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-theanine 200 mg to 400 mg
Study: 34514770
Drug: Intrauterine infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrauterine infusion of PRP (0.5CC, contained platelet 4-5 times more than a peripheral blood sample, performed 48 hours before blastocyst transfer)
Study: 32963066
Drug: Maternally administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maternally administered malnutrition monitoring system (MAMMS) with SMS prompts for MUAC measurement.
Study: 34836277
Drug: Capsule containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing spray-dried powder from pineapple juice broth fermented with Lactobacillus paracasei IJH-SONE68, taken daily for 12 weeks
Study: 34836277
Drug: Placebo, taken
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, taken daily for 12 weeks
Study: 34836277
Drug: Capsule containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsule containing spray-dried powder from pineapple juice broth fermented with Lactobacillus paracasei IJH-SONE68
Study: 35552172
Drug: Cardiac rehabilitation
Normalized name: Leonurus cardiaca extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardiac rehabilitation combined with routine treatment
Study: 35552172
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment only (positive control group)
Study: 36459138
Drug: High-dose erythropoietin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose erythropoietin (2000 units/kg body weight)
Study: 32558052
Drug: Mirabegron (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (200 mg one dose p.o.)
Study: 35485627
Drug: Telephone follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone follow-up (four 30-minute sessions twice a week for a month)
Study: 34989412
Drug: Topical nasal
Normalized name: Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical nasal anesthetic (TNA) - viscous lidocaine
Study: 33915390
Drug: No endovascular
Approvals — FDA: no, EMA: no, PMDA: no
Description: No endovascular therapy (no-EVT)
Study: 32003938
Drug: rosuvastatin 20
Normalized name: rosuvastatin 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: rosuvastatin 20 mg + amlodipine 10 mg
Study: 33773639
Drug: Attention control
Normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Attention control medication list app (control arm)
Study: 36138363
Drug: i-gel combined
Normalized name: iobenguane I-131
Approvals — FDA: no, EMA: no, PMDA: no
Description: i-gel combined with flexible bronchoscopy-guided intubation
Study: 36464680
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (APP+DOC)
Study: 36464680
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual group (TAU)
Study: 33331850
Drug: Both treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatment groups (IOL and CL)
Study: 35896083
Drug: Relefact LHRH®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relefact LHRH® (100 μg/m2)
Study: 32358357
Drug: Baseline ALT
Normalized name: ALT-801
DrugBank: ALT-801 (DB15386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline ALT >133 U/L
Study: 35332737
Drug: Non-invasive bi-level
Normalized name: bis-ethoxydiglycol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-invasive bi-level positive airway pressure (BiPAP) ventilation in treatment group 1
Study: 35332737
Drug: High-flow nasal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-flow nasal cannula (HFNC) oxygen therapy in treatment group 2
Study: 35332737
Drug: Treatment groups
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment groups (1 and 2)
Study: 33602198
Drug: Low-level laser
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-level laser therapy (LLLT) using laser diode 940 nm
Study: 34413118
Drug: Native human
Normalized name: Insulin Human
DrugBank: Insulin human (DB00030)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Native human insulin (HI)
Study: 33253354
Drug: Verubecestat (BACE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verubecestat (BACE inhibitor)
Study: 35834528
Drug: High-dose micronutrient-antioxidant
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose micronutrient-antioxidant supplement
Study: 35834528
Drug: RDA supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: RDA supplement
Study: 32720121
Drug: NACT (Neoadjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: NACT (Neoadjuvant Chemotherapy)
Study: 35763437
Drug: Snail secretion
Normalized name: SNAIL SECRETION FILTRATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Snail secretion filtrate, Calendula officinalis, and Glycyrrhiza glaba root extract combination serum (SCGS)
Study: 35763437
Drug: SCGS with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: SCGS with concurrent acne treatments
Study: 35217746
Drug: Professional oral
Normalized name: Dentek Professional Oral Care Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional oral hygiene care administered every 24 hours
Study: 35217746
Drug: Professional oral
Normalized name: Dentek Professional Oral Care Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Professional oral hygiene care
Study: 34608929
Drug: Tirzepatide (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide (1, 5, 10, 15 mg)
Study: 33370506
Drug: Voice Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voice Therapy (VT)
Study: 32577737
Drug: Combination group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination group (resistance‐band and Biomechanical Ankle Platform System)
Study: 33608048
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg tianeptine
Study: 32717713
Drug: Adjunctive brivaracetam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive brivaracetam (BRV) 100 and 200 mg/day
Study: 35263517
Drug: 4 months
Normalized name: leuprolide 30 mg/4 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 months of standard first-line antituberculosis treatment
Study: 35263517
Drug: 6 months
Normalized name: leuprolide 45 mg/6 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 months of standard first-line antituberculosis treatment
Study: 35263517
Drug: 4 months
Normalized name: leuprolide 30 mg/4 months intramuscular kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 months of treatment
Study: 34004483
Drug: Evinacumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evinacumab (15 mg/kg intravenously once monthly)
Study: 34455435
Drug: Active oil
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active oil (high-dose, purified omega-3 fatty acids) mimicking REDUCE-IT
Study: 34455435
Drug: Active oil
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active oil (high-dose, purified omega-3 fatty acids) mimicking STRENGTH
Study: 36131603
Drug: Capmatinib 400
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capmatinib 400 mg bid
Study: 35725494
Drug: 0.5% lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5% lidocaine continuous parasternal block at 7 ml/hour for 72 hours
Study: 35285173
Drug: liraglutide 1.8 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 1.8 mg
Study: 35285173
Drug: liraglutide 0.9 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: liraglutide 0.9 mg
Study: 35613822
Drug: Sintilimab 200
Normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab 200 mg plus bevacizumab 15 mg/kg every 3 weeks
Study: 34652968
Drug: Standard five-drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard five-drug interval compressed chemotherapy (regimen A) for 17 cycles
Study: 34652968
Drug: Experimental therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental therapy with five cycles of vincristine, topotecan, and cyclophosphamide (VTC) within the 17 cycles (regimen B)
Study: 32747497
Drug: BNP infusion
Normalized name: BNP
DrugBank: Nesiritide (DB04899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BNP infusion (0.006 μg/kg/min for 72 hours)
Study: 33798307
Drug: Comparison between
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison between acupuncture and sham acupuncture groups after treatment.
Study: 34297268
Drug: Sorafenib 400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sorafenib 400 mg twice daily for 10 days
Study: 33320286
Drug: Hypofractionated RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated RT with sequential boost (HFseq)
Study: 33320286
Drug: Normofractionated RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normofractionated RT with sequential boost (NFseq)
Study: 35190414
Drug: SFP10‐14 intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: SFP10‐14 intervention comprising seven weekly sessions
Study: 616708360
Drug: Khanda Pippali
Normalized name: Chanda Root
DrugBank: Angelica archangelica root (DB14283)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Khanda Pippali Avaleha (10 g orally for 60 days)
Study: 616708360
Drug: Omeprazole (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (20 mg once a day for 60 days, empty stomach)
Study: 34465402
Drug: Direct maxillary
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct maxillary sinus saline irrigation with systemic antibiotics and topical sprays (n = 24)
Study: 34465402
Drug: Pharmacological therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological therapy alone (n = 15)
Study: 32090788
Drug: Rhodiola capsule
Normalized name: RHODIOLA ROSEA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhodiola capsule (0.6 g/day) combined with sertraline